BioCentury
ARTICLE | Finance

3Q Financial Markets Preview: Flavored with Phase III

Buysiders picks of biotech stocks to watch in 2H11

July 4, 2011 7:00 AM UTC

The upcoming clinical and regulatory calendar isn't as densely packed as it was in the first half. But biotech investors are looking especially to Phase III data across all market cap segments through year end.

Among the big caps, several buysiders are keen on upcoming Phase III data from Biogen Idec Inc. and Gilead Sciences Inc., companies that already have had strong gains this year...